Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NeuroBo Pharmaceuticals, Inc. (NRBO : NSDQ)
 
 • Company Description   
NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.56 Daily Weekly Monthly
20 Day Moving Average: 208,451 shares
Shares Outstanding: 26.66 (millions)
Market Capitalization: $15.06 (millions)
Beta: 0.66
52 Week High: $5.63
52 Week Low: $0.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.94% -26.72%
12 Week -24.16% -16.62%
Year To Date -53.69% -43.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 Berkeley Street Office 19th Floor
-
Boston,MA 02116
USA
ph: 857-702-9600
fax: 734-293-0444
ir@neurobopharma.com http://www.neurobopharma.com
 
 • General Corporate Information   
Officers
Ben Gil Price - President and Chief Executive Officer
Andrew Koven - Chairperson
Jason L. Groves - Director
Richard J. Kang - Director
Hyung Heon Kim - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 64132R107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 26.66
Most Recent Split Date: 12.00 (0.04:1)
Beta: 0.66
Market Capitalization: $15.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.26
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -30.77%
vs. Previous Quarter: -6.25%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -140.86
12/31/21 - -141.03
09/30/21 - -143.25
ROA
03/31/22 - -120.96
12/31/21 - -122.87
09/30/21 - -117.27
Current Ratio
03/31/22 - 8.87
12/31/21 - 7.69
09/30/21 - 4.13
Quick Ratio
03/31/22 - -
12/31/21 - 7.69
09/30/21 - 4.13
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.45
12/31/21 - 0.55
09/30/21 - 0.27
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©